Charles N. York II - 17 Feb 2023 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role: COO, CFO and Secretary
Signature: /s/ Charles N. York II
Issuer symbol: DAWN
Transactions as of: 17 Feb 2023
Net transactions value: -$187,790
Form type: 4
Filing time: 21 Feb 2023, 16:01:53 UTC
Previous filing: 17 Feb 2023
Next filing: 17 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DAWN	Common Stock	Sale	$187,790	-9,377	-3.5%	$20.03	262,128	17 Feb 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.